PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia

Umberto Campia, Linda A. Matuskey, Manfredi Tesauro, Carmine Cardillo, Julio A. Panza

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This study tested the hypothesis that pioglitazone reduces endothelin-1 activity in the forearm vasculature in non-diabetic patients with hypertension or hypercholesterolemia and variable degrees of insulin resistance.
Original languageEnglish
Pages (from-to)436-440
Number of pages5
JournalAtherosclerosis
Volume234
DOIs
Publication statusPublished - 2014

Keywords

  • Biological Markers
  • C-Reactive Protein
  • Cross-Over Studies
  • District of Columbia
  • Double-Blind Method
  • Endothelial function
  • Endothelin A Receptor Antagonists
  • Endothelin activity
  • Endothelin-1
  • Endothelium, Vascular
  • Fatty Acids, Nonesterified
  • Forearm
  • Humans
  • Hypercholesterolemia
  • Hypertension
  • Insulin
  • Insulin Resistance
  • Insulin resistance
  • Lipoproteins, HDL
  • PPAR gamma
  • Peptides, Cyclic
  • Thiazolidinediones
  • Time Factors
  • Treatment Outcome
  • Triglycerides
  • Vasodilation

Fingerprint

Dive into the research topics of 'PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia'. Together they form a unique fingerprint.

Cite this